Based on the measurements of operating efficiency obtained from Neuropace's historical financial statements, Neuropace is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. At present, Neuropace's Total Current Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 8.4 M, whereas Other Current Liabilities is forecasted to decline to about 8.5 M. Key indicators impacting Neuropace's financial strength include:
The essential information of the day-to-day investment outlook for Neuropace includes many different criteria found on its balance sheet. An individual investor should monitor Neuropace's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Neuropace.
Please note, the presentation of Neuropace's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuropace's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuropace's management manipulating its earnings.
Neuropace Stock Summary
Neuropace competes with Electromed, Orthopediatrics Corp, SurModics, Paragon 28, and Nevro Corp. NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 187 people.
Comparative valuation techniques use various fundamental indicators to help in determining Neuropace's current stock value. Our valuation model uses many indicators to compare Neuropace value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neuropace competition to find correlations between indicators driving Neuropace's intrinsic value. More Info.
Neuropace is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Neuropace's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Neuropace by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Neuropace Systematic Risk
Neuropace's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Neuropace volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Neuropace correlated with the market. If Beta is less than 0 Neuropace generally moves in the opposite direction as compared to the market. If Neuropace Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Neuropace is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Neuropace is generally in the same direction as the market. If Beta > 1 Neuropace moves generally in the same direction as, but more than the movement of the benchmark.
Neuropace Thematic Clasifications
Neuropace is part of Medical Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Neuropace Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neuropace's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Neuropace growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.47
At present, Neuropace's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Neuropace March 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neuropace help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neuropace. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neuropace based on widely used predictive technical indicators. In general, we focus on analyzing Neuropace Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neuropace's daily price indicators and compare them against related drivers.
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.